Heart Transplant Recipient Describes Insurance Coverage That Does Not Provide Medication Access
A heart transplant patient reports that insurance approved everolimus but required repeated prior authorizations and peer reviews before denying the prescription. After public appeals, the insurer approved the drug at a cost of roughly $500 per month. The patient now receives the medication through private assistance.
nypost.comA heart transplant recipient reports that insurance coverage for a prescribed anti-rejection drug did not result in actual access to the medication. The patient, Payton Herres, states that her transplant team prescribed everolimus, which is FDA-approved for liver and kidney transplants but used off-label for heart transplant patients.
She writes that the drug can help preserve kidney function and reduce the risk of cardiac allograft vasculopathy. On paper, the medication was covered. In practice, the insurer required multiple prior authorizations and peer-to-peer reviews before denying the prescription.
Herres states that she was days away from running out of medication and experienced sleepless nights and stress at work.
Herres posted on Facebook seeking help, and the post was shared more than 4,900 times. Her donor's mother offered to pay for the medication. Following the public attention, Anthem approved the prescription. The cost remains approximately $500 for a 30-day supply.
Herres states that she earns just over $35,000 per year and that mail-order delivery is not a safe option for transplant medication. She is currently receiving the drug through assistance from Claimable CEO Warris Bokhari and businessman Mark Cuban via the Mark Cuban Cost Plus Drug Company.
Herres states that similar access problems affect other patients even when coupons or savings programs are available. She uses the term "ghost approval" to describe coverage that exists on paper but does not provide reliable access to prescribed medication.
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Story details
Related Stories
nypost.comWHO Reports Five Recoveries From Rare Ebola Strain in Congo and Uganda
The World Health Organization said five people have recovered from the Bundibugyo strain despite the absence of approved treatments or vaccines. At least 906 suspected cases and 223 deaths have been reported across the affected region.
citizen.co.zaEbola Outbreak in Eastern Congo Reaches 906 Suspected Cases
WHO Director-General Tedros Adhanom Ghebreyesus arrived in Bunia on May 30 to assess the response to a Bundibugyo virus outbreak that has killed 223 people. Officials reported cases spreading to North Kivu and South Kivu, while Uganda confirmed nine infections.
France 24Zambia’s Kabwe Residents Sue Mining Company Over Lead Contamination
Children in Kabwe, Zambia, show blood lead levels above World Health Organization limits after decades of mining. An estimated 140,000 women and children have joined a class-action lawsuit against Anglo American South Africa Limited.